LON:MXCT - MaxCyte Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: GBX 1,240
  • Forecasted Upside: 30.53 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
GBX 950
▲ +14 (1.50%)

This chart shows the closing price for MXCT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New MaxCyte Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MXCT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MXCT

Analyst Price Target is GBX 1,240
▲ +30.53% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for MaxCyte in the last 3 months. The average price target is GBX 1,240, with a high forecast of GBX 1,240 and a low forecast of GBX 1,240. The average price target represents a 30.53% upside from the last price of GBX 950.

This chart shows the closing price for MXCT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in MaxCyte.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/3/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/3/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/28/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/28/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/27/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/15/2021Numis SecuritiesReiterated RatingBuyGBX 1,240
9/19/2017Panmure GordonReiterated RatingBuyGBX 338
4/25/2017Panmure GordonLower Price TargetBuyGBX 349 ➝ GBX 338
3/20/2017Panmure GordonBoost Price TargetBuyGBX 280 ➝ GBX 349
2/22/2017Panmure GordonReiterated RatingBuyGBX 266
1/24/2017Panmure GordonBoost Price TargetBuyGBX 170 ➝ GBX 266
1/6/2017Panmure GordonReiterated RatingBuyGBX 170
12/21/2016Panmure GordonReiterated RatingBuyGBX 170
9/27/2016Panmure GordonReiterated RatingBuyGBX 170
9/20/2016Panmure GordonReiterated RatingBuyGBX 170
9/6/2016Panmure GordonReiterated RatingBuyGBX 170
(Data available from 7/28/2016 forward)
MaxCyte logo
MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers; and ExPERT brand series of instruments and consumables, as well as insourcing services. In addition, it develops CARMA, a novel and proprietary technology for the development of non-viral, human messenger RNA-based, chimeric antigen receptor or T-cell receptor redirected immune cell therapies. The company licenses and sells its instruments and technology; and sells its products to drug developers and biopharmaceutical companies. It has a clinical and commercial license agreement with Allogene Therapeutics, Inc. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.
Read More

Today's Range

Now: GBX 950
Low: 938
High: 960

50 Day Range

MA: GBX 940.32
Low: 890
High: 1,120

52 Week Range

Now: GBX 950
Low: 234
High: 1,150

Volume

74,436 shs

Average Volume

203,000 shs

Market Capitalization

£807.97 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of MaxCyte?

The following equities research analysts have issued research reports on MaxCyte in the last year: Numis Securities Ltd.
View the latest analyst ratings for MXCT.

What is the current price target for MaxCyte?

1 Wall Street analysts have set twelve-month price targets for MaxCyte in the last year. Their average twelve-month price target is GBX 1,240, suggesting a possible upside of 30.5%. Numis Securities Ltd has the highest price target set, predicting MXCT will reach GBX 1,240 in the next twelve months. Numis Securities Ltd has the lowest price target set, forecasting a price of GBX 1,240 for MaxCyte in the next year.
View the latest price targets for MXCT.

What is the current consensus analyst rating for MaxCyte?

MaxCyte currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MXCT will outperform the market and that investors should add to their positions of MaxCyte.
View the latest ratings for MXCT.

What other companies compete with MaxCyte?

How do I contact MaxCyte's investor relations team?

MaxCyte's physical mailing address is 22 Firstfield Rd Ste 110, GAITHERSBURG, MD 20878-1795, United States. The company's listed phone number is +1-301-9441700. The official website for MaxCyte is www.maxcyte.com.